Wednesday, November 18, 2026

BioVie Reveals New Long COVID Biomarker Findings From Phase 2 Bezisterim Trial

Nov 17, 2026

BioVie, a clinical-stage biotechnology company developing therapies for neurological and neurodegenerative diseases, has announced new clinical and biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim, presented November 13, 2026, at the 4th Long COVID International Conference in Nice, France. Exploratory analyses identified at least two biologically distinct Long COVID patient subgroups, suggesting that different underlying biological mechanisms may influence treatment response. Patients with elevated inflammatory biomarkers demonstrated the greatest treatment-related improvements in objective cognitive outcomes, while patients with low white blood cell and myeloid cell levels showed larger treatment effects on fatigue and post-exertional malaise.

The presentation also highlighted neuropeptide Y (NPY), a signaling molecule involved in communication between the nervous, neuroendocrine, autonomic, and immune systems. According to BioVie, NPY is being added to the NIH RECOVER biomarker prioritization list, potentially supporting further research into Long COVID’s underlying biology. These exploratory Phase 2 findings may help researchers better understand patient differences and guide future clinical development of bezisterim, an investigational treatment that has not been approved for Long COVID. Jane King reports for NewsOut.

#BioVie #Bezisterim #LongCOVID #LongCOVIDResearch #Biomarkers #ClinicalTrials #Phase2 #ADDRESSLC #NeuropeptideY #ChronicFatigue #BrainFog #Biotechnology #MedicalResearch #JaneKing #NewsOut